More Information

Blase C. Billack

Associate Professor
Pharmaceutical Sciences
Dr. Billack completed his B.S. degree in Chemistry at the University of Richmond. Under the mentorship of Professor Jeffrey Laskin, Dr. Billack earned his PhD in Toxicology from the Joint Graduate Program in Toxicology UMDNJ/Rutgers. He then pursued an additional two years of postdoctoral training in the area of molecular oncology at the Strang Cancer Prevention Center, on the campus of the Rockefeller University, under the direction of Dr. Alvaro Monteiro where he worked on BRCA 1 mutations and hereditary breast cancer. Dr. Billack is currently an Associate Professor in the College of Pharmacy and Health Sciences at St. John’s University. He has taught at both the NYC campus and Rome campus through the St. John’s University Discover Italy program. Dr. Billack has mentored 9 undergraduate and 11 graduate students. He has over 30 peer-reviewed publications, mostly in the area of in vitro toxicology but recently has expanded the focus of his lab towards rodent models of chemical injury. The primary goal of the ongoing research in his lab is to identify novel and effective countermeasures to chemical threats. He has been a member of the Society of Toxicology since 1999. He is also among the Founding Editors of the Journal of Toxicological Education and has recently published an article in that journal (www.jtoxed.org). current as of March 13, 2015.

Courses Taught

PHM
201
PHARM AUTONOMIC NERVOUS SYS
PHR
5106
D&D:ENDO & REPRODUCTIVE SYS
PHS
2201
BIOPHARMACEUTICAL CHEMISTRY
PHS
3509
INTRODUCTION TO PHARMACOLOGY

Select Publications

Journal Articles

Billack, B. C. (2014). Selected ebselen analogs reduce mechlorethamine toxicity in vitro.. Cutaneous and Ocular Toxicology.

Billack, B. C. (2014). Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine. . Journal of Applied Toxicology.

Billack, B. C. (2013). Ebselen reduces the toxicity of mechlorethamine in A-431 cells via inhibition of apoptosis.. Journal of Biochemical and Molecular Toxicology.

Billack, B. C. (2013). Selected ebselen analogues reduce 2-chloroethyl ethyl sulphide (CEES) Toxicity in A-431 Cells.. Archives of Industrial Hygiene and Toxicology.

Billack, B. C. (2010). BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. . American Journal of Pathology.

Billack, B. C. (2009). Analysis of missense, frameshift, and splicing variants of BRCA1. . Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis.

Billack, B. C. (2008). Reduction of vesicant toxicity by butylated hydroxyanisole.. Cutaneous and Ocular Toxicology.

Billack, B. C. (2007). Ebselen protects brain, skin, lung and blood cells from mechloroethamine toxicity. . Toxicology and Industrial Health.

Billack, B. C. (2005). BRCA1 in breast and ovarian cancer predisposition. Cancer Letters.

Billack, B. C. (2004). Methods to classify BRCA1 variants of uncertain clinical significance. . Cancer Biology and Therapy.

Billack, B. C. (2002). A naturally- occurring allele of BRCA1 encoding for a temperature-sensitive mutant protein.. Cancer Biology and Therapy.

Billack, B. C. (2002). Mutations in the BRCT domain confer temperature-sensitivity to BRCA1 in transcription activation.. Cancer Biology and Therapy.

Book Chapters

Billack, B. C. (2012). Potential Tumor Biomarkers for Ovarian Cancer. In: Ovarian Cancer - Basic Science Perspective. InTech..